ArticleActa oncologica (Stockholm, Sweden)2025
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone metastases occur in up to 75% of metastatic breast cancer (MBC) cases. Advances in imaging now allow earlier detection, even during the oligometastatic phase. Radiotherapy (RT) is increasingly used in asymptomatic patients with ≤5 bone lesions, however standardised guidelines for dose and target volumes remain lacking. This study evaluates the outcomes of a simultaneous integrated boost (SIB) using intensity-modulated radiotherapy (IMRT) to deliver ablative doses to macroscopic bone lesions.
methodsThis retrospective study analysed MBC patients treated with SIB-IMRT for bone metastases between January 2014 and January 2022. The primary endpoint was freedom from local progression (FFLP); secondary endpoints included disease progression after radiotherapy (DP-AR) and overall survival (OS). Subgroup analyses were performed according to age, immunophenotype, and line of therapy.
resultsAmong 954 patients treated with RT, 85 received SIB-IMRT (6-8 Gy per fraction, 5 fractions). Median follow-up was 41 months. Nineteen patients (22.4%) had a single bone metastasis, 23.5% were oligometastatic, and 54.1% were plurimetastatic. Median FFLP was 17 months; only 7% experienced local relapse at the SIB site. While DP-AR was 13.2 months, median OS reached 82.7 months. No significant correlation was found between local relapse and age, immunophenotype, or systemic therapy. Immunophenotype significantly influenced DP-AR (p = 0.002), while DP-AR and OS were not significantly associated with local progression.
interpretationSIB-IMRT for bone metastases in MBC is feasible and effective, with encouraging local control and minimal toxicity. Prospective studies are warranted to optimise dose escalation and explore synergistic effects with systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.